Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Macrophage-produced VEGFC is induced by efferocytosis to ameliorate cardiac injury and inflammation
Kristofor E. Glinton, … , Guillermo Oliver, Edward B. Thorp
Kristofor E. Glinton, … , Guillermo Oliver, Edward B. Thorp
Published March 10, 2022
Citation Information: J Clin Invest. 2022;132(9):e140685. https://doi.org/10.1172/JCI140685.
View: Text | PDF
Research Article Inflammation Vascular biology

Macrophage-produced VEGFC is induced by efferocytosis to ameliorate cardiac injury and inflammation

  • Text
  • PDF
Abstract

Clearance of dying cells by efferocytosis is necessary for cardiac repair after myocardial infarction (MI). Recent reports have suggested a protective role for vascular endothelial growth factor C (VEGFC) during acute cardiac lymphangiogenesis after MI. Here, we report that defective efferocytosis by macrophages after experimental MI led to a reduction in cardiac lymphangiogenesis and Vegfc expression. Cell-intrinsic evidence for efferocytic induction of Vegfc was revealed after adding apoptotic cells to cultured primary macrophages, which subsequently triggered Vegfc transcription and VEGFC secretion. Similarly, cardiac macrophages elevated Vegfc expression levels after MI, and mice deficient for myeloid Vegfc exhibited impaired ventricular contractility, adverse tissue remodeling, and reduced lymphangiogenesis. These results were observed in mouse models of permanent coronary occlusion and clinically relevant ischemia and reperfusion. Interestingly, myeloid Vegfc deficiency also led to increases in acute infarct size, prior to the amplitude of the acute cardiac lymphangiogenesis response. RNA-Seq and cardiac flow cytometry revealed that myeloid Vegfc deficiency was also characterized by a defective inflammatory response, and macrophage-produced VEGFC was directly effective at suppressing proinflammatory macrophage activation. Taken together, our findings indicate that cardiac macrophages promote healing through the promotion of myocardial lymphangiogenesis and the suppression of inflammatory cytokines.

Authors

Kristofor E. Glinton, Wanshu Ma, Connor Lantz, Lubov S. Grigoryeva, Matthew DeBerge, Xiaolei Liu, Maria Febbraio, Mark Kahn, Guillermo Oliver, Edward B. Thorp

×

Figure 9

Evidence for heightened cardiac and macrophage inflammation in myeloid Vegfc–deficient mice.

Options: View larger image (or click on image) Download as PowerPoint
Evidence for heightened cardiac and macrophage inflammation in myeloid V...
(A) Flow cytometric analysis of the ischemic AAR, 7 days after MI revealed heightened levels of CD11b+Ly6g+ neutrophils, Ly6chi monocytes, CD11b+CD11c+MHCIIhi DCs, and CD64+F4/80+ macrophages. Importantly, the ratio of MHCIIlo to MHCIIhi macrophages within the infarcted myocardium was significantly altered in Vegfc-deficient mice. n = 7–9 per group. *P < 0.05, by 2-tailed, unpaired t test. (B) BMDMs from Vegfcfl/fl and Vegfcfl/fl LysmCre mice were assessed for indicators of heightened inflammation. Transcript levels were measured by qPCR. An increase in markers of inflammation in Vegfc-deficient macrophages was observed along with reduced expression levels of Arg1. n = 3–6 per group. *P < 0.05 and **P < 0.004, by 2-tailed, unpaired t test. (C) VEGFC suppressed mRNA expression of inflammatory cytokines. qPCR of LPS-treated macrophages in culture treated with recombinant VEGFC versus control. n = 6 per group. *P < 0.05 and **P < 0.001, by 2-tailed, unpaired t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts